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Summary
Autocrine, paracrine, and juxtacrine are recognized modes
of action for mammalian EGFR ligands including EGF,
TGF-a (TGFa), amphiregulin (AREG), heparin-binding EGF-
like growth factor (HB-EGF), betacellulin, epiregulin, and
epigen. We identify a new mode of EGFR ligand signaling
via exosomes. Human breast and colorectal cancer cells
release exosomes containing full-length, signaling-compe-
tent EGFR ligands. Exosomes isolated from MDCK cells
expressing individual full-length EGFR ligands displayed
differential activities; AREG exosomes increased invasive-
ness of recipient breast cancer cells 4-fold over TGFa or
HB-EGF exosomes and 5-fold over equivalent amounts of
recombinant AREG. Exosomal AREG displayed significantly
greater membrane stability than TGFa or HB-EGF. An
average of 24 AREG molecules are packaged within an
individual exosome, and AREG exosomes are rapidly inter-
nalized by recipient cells. Whether the composition and
behavior of exosomes differ between nontransformed and
transformed cells is unknown. Exosomes from DLD-1 colon
cancer cells with a mutant KRAS allele exhibited both higher
AREG levels and greater invasive potential than exosomes
from isogenically matched, nontransformed cells in which
mutant KRAS was eliminated by homologous recombina-
tion. We speculate that EGFR ligand signaling via exosomes
might contribute to diverse cancer phenomena such as field
effect and priming of the metastatic niche.
Results and Discussion
EGFR Ligands Are Present in Exosomes
EGFR ligands are produced as type 1 transmembrane proteins
[1]. How they are trafficked, processed, and released deter-
mine the range, amplitude, and duration of downstream7These authors contributed equally to this work
*Correspondence: robert.coffey@vanderbilt.eduEGFR signaling [2]. This study was spurred by our detection
of full-length HB-EGF in the conditioned medium of MDA-
MB-231 breast cancer cells without its presence at the plasma
membrane (PM) (not shown). EGFR ligands act as soluble
autocrine and paracrine factors or in a juxtacrine manner as
full-length, uncleaved, cell surface ligands [3, 4]. However,
we hypothesized that extracellular release of HB-EGF in
exosomes might explain this observation. Exosomes are
30-100 nm extracellular nanovesicles produced by intralume-
nal budding of multivesicular bodies (MVB) and MVB-PM
fusion [5]. We purified <200-nm-sized extracellular vesicles
that were from MDA-MB-231 cell conditioned medium by
sucrose gradient fractionation (Experimental Procedures).
These fractions were immunoblotted; fractions 4–6 contained
peak levels of HB-EGF and exosomal proteins CD9, ADAM-10,
and ADAM-17 [6, 7] but were negative for the ERmarker calre-
ticulin (Figure 1A). Transmission electron microscopy (TEM) of
fractions 4–6 showed 30–50 nm vesicles with morphological
characteristics of exosomes (Figure S1A) [5].
To determine whether other EGFR ligands were localized in
these extracellular vesicles, we utilized fluorescence-acti-
vated vesicle sorting (FAVS). We developed this approach to
isolate small (<100 nm) vesicles [8] and to perform vesicle-
by-vesicle analysis and thus avoid signal loss due to bulk
measurements and signal averaging. HB-EGF and TGFa
were detected in extracellular vesicles purified from MDA-
MB-231 cells and HCA-7 colorectal cancer cells, whereas
AREG was detected only in HCA-7 vesicles (Figure 1B; see
also Figure S1B). These results provide the first evidence
that EGFR ligands are released in extracellular vesicles.
To be more confident that EGFR ligand-containing extracel-
lular vesicles are exosomes, we immunoblotted whole-cell
lysates (WCL) or vesicle preparations from the conditioned
medium of MDCK cells stably expressing AREG (MDCK
AREG) for AREG, exosomal markers (Hsp-70 [9–11], Tsg101
[12, 13], and flotillin-1 [14–16]), nuclear markers (lamin A/C
and poly [ADP-ribose] polymerase [PARP]), the ER marker
(calreticulin), and the mitochondrial marker (voltage-depen-
dent anion channel [VDAC]). The vesicle preparations con-
tained exosomal markers but not the other organelle markers
(Figure S1C), indicating that these vesicles are likely exo-
somes. Furthermore, the calculated mean diameter from three
independent sets of vesicles from the conditioned medium of
MDCK AREG cells was 51.3 nm (Figure 1C), a size previously
described as characteristic of exosomes [5]. We detected
only scattered vesicles larger than 100 nm and little cellular
debris. We cannot exclude the possibility that our extracel-
lular-vesicle preparations also contain shedding vesicles.
However, shed vesicles are classically defined as up to 1 mm
in diameter; smaller shedding vesicles have been described,
but they are typically not less than 100–200 nm [17]. Therefore,
on the basis of their size (Figure 1C; see also Figure S1A) and
composition (Figure 1A; see also Figure S1C), our vesicle prep-
arations appear to be highly enriched for exosomes.
Utilizing FAVS, we tested whether exosomal EGFR ligands
were full-length and displayed in a proper orientation to
engage receptors on recipient cells. Using N- or C-terminus-
specific antibodies, we found the N terminus of endogenous
Figure 1. Biochemical Analysis of Exosomes Isolated fromMDA-MB-231 Breast Cancer Cells, HCA-7 Colon Cancer Cells, and MDCK Cells Stably Express-
ing EGFR Ligands
(A) Extracellular vesicles were purified from MDA-MB-231 conditioned medium by sucrose gradient fractionation (Experimental Procedures). Fractions
1–11 and whole-cell lysate (WCL), in lane 12, were separated by SDS-PAGE, and equal volumes were immunoblotted with the indicated antibodies.
(B) Representative histograms from FAVS analysis of exosomes isolated from HCA-7 cells via the indicated ectodomain antibodies. Horizontal bars repre-
sent the gate, and percentage of positive exosomes is indicated.
(C) Relative size of AREG exosomes. Three independent exosome preparations from MDCK cells stably expressing AREG were negatively stained and
viewed by TEM. A representative field image (upper) shows vesicles with a smooth, saucer-like morphology characteristic of exosomes. Themean diameter
of 300 vesicles was calculated from TEM images. The scale bar represents 250 nm.
(D) Topology of endogenous TGFa and heterologous AREG in exosomes. Exosomes from MDA-MB-231 cells (left panel) were subjected to FAVS analysis
with antibodies against the ectodomain (top) and cytoplasmic tail (bottom) of TGFa. Exosomes from MDCK cells expressing full-length AREG with a C-ter-
minal HA tag (middle panel) were subjected to FAVS analysis with an AREG ectodomain antibody (top) or an HA antibody (bottom). Horizontal bars represent
the gate, and the percentage of positive exosomes is indicated. Right panel: Exosomes were isolated from conditioned medium of MDCK cells stably
expressing HA-tagged AREG or HB-EGF and immunoblotted with an anti-HA antibody so that cell-surface isoforms of AREG (arrows) could be detected.
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780TGFa on the outside of MDA-MB-231 exosomes. Likewise,
heterologous AREG (both wild-type AREG and C-terminally
HA-tagged AREG expressed in MDCK cells) exhibited the
same exosomal topology as TGFa (Figure 1D). These results
demonstrate that exosomal TGFa and AREG are in a
signaling-competent orientation such that the N terminus is
available to engage recipient cell EGFR.
AREG-Containing Exosomes Induce Recipient
Cell Invasion
To examine the function of individual EGFR ligands, we puri-
fied exosomes from parental MDCK cells expressing unde-
tectable levels of EGFR ligands [18] and MDCK cells overex-
pressing HB-EGF, TGFa, or AREG. As a functional readout ofexosome activity, we assessed the effect of exosomes on
recipient cancer cell invasion, a hallmark of malignancy. Using
a modified Boyden chamber assay, we found that AREG
exosomes stimulated similar levels of invasion for MDA-MB-
231-derived LM2-4175 and LMO-1833 recipient cells that
metastasize to lung and bone, respectively [19]; results from
LM2-4175 cells are shown. We determined that exosomes
purified from the conditionedmedium ofMDCK cells overnight
or after a 2 hr exposure to ionomycin exhibited identical inva-
sive effects; thus, these two preparations were pooled in all
subsequent experiments (Figure S2A).
For the invasion assays, LM2-4175 cells were treated with
serum-free medium alone or with the following supplements:
MDCK AREG WCL or parental, HB-EGF, TGFa, or AREG
Figure 2. Exosomes from AREG-Expressing MDCK Cells Induce the Highest Invasive Activity in Recipient Breast Cancer Cells
(A and B) LM2-4175 cells were incubated for 2 hr with serum-free medium containing 100 mg/ml BSA (CTL), 100 mg/ml of MDCK-AREGWCL, and 100 mg/ml
of parental MDCK cell exosomes, TGFa exosomes, HB-EGF exosomes, or AREG exosomes. Cells then were plated in Matrigel-coated Boyden chambers,
and the numbers of cells on the bottom of Transwell filters was imaged (A) or quantified (B) after 72 hr (Experimental Procedures). (B) Data represent the
mean +/2 SD.
(C) LM2-4175 cells were incubated with exosomes containing 20 ng/ml of AREG as measured by ELISA or 20 ng/ml recombinant human ligands. A similar
concentration of AREG was found in MDCK exosomes as measured by ELISA. Data represent the mean 6 SD.
(D) LM2-4175 cells were treated with increasing concentrations of AREG exosomes with or without pretreatment with an AREG neutralizing monoclonal
antibody, 6R1C2.4 (20 mg/ml). Data represent the mean 6 SD, p < 0.0001 (*).
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781exosomes. Treatment-containing, serum-free medium was
replaced every 24 hr, and the number of cells that invaded
through Matrigel to the undersurface of Transwell filters was
quantified after 72 hr. LM2-4175 cell invasion was not affected
by serum-free medium, and increases in serum concentration
increased invasion (not shown). AREG exosomes enhanced
invasiveness of LM2-4175 cells 4-fold over TGFa or HB-EGF
exosomes and 5-fold over parental MDCK exosomes or
MDCK AREGWCL (Figures 2A and 2B). Two experiments per-
formed in duplicate showed that the concentration per mili-
gram of exosomal protein was 793.5 ng of AREG, 749 ng of
TGFa, and 931.5 ng of HB-EGF, suggesting similar amounts
of the ligands in MDCK cell exosomes. Thus, differences in
exosomal ligand concentration cannot explain the greater
invasive potential of AREG exosomes.
We next compared the invasive potential of AREG exo-
somes to that of recombinant ligands. ELISA showed that
the concentration of AREG exosomes was 20 ng/ml (Experi-
mental Procedures). At this concentration of exosomal AREGand recombinant ligands, AREG exosomes increased the
number of invading LM2-4175 cells 5-fold more than recombi-
nant ligands (Figure 2C). In a concentration-response experi-
ment, 100 ng/ml recombinant AREG (Figure S2B) did not
achieve the invasive effect of exosomes containing 20 ng/ml
AREG (Figures 2B and 2C). In a separate experiment, AREG
exosomes enhanced wound healing in comparison to serum-
free control or recombinant AREG (Figure S2C). Combined,
these results demonstrate that AREG exosomes impart
greater recipient cell invasiveness than parental MDCK exo-
somes, exosomes containing other EGFR ligands, or recombi-
nant EGFR ligands.
To address how much of the effect of AREG exosomes is
due to AREG itself, we treated recombinant AREG or AREG
exosomes with or without AREG-neutralizing antibody for
1 hr prior to incubation with LM2-4175 cells. Regardless of
exosome concentration, AREG-neutralizing antibody reduced
the number of invasive cells by approximately 50% (Figure 2D).
Because all known biological effects of AREG are mediated by
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782EGFR binding, our results suggest the invasive effect of AREG
exosomes is due, at least in part, to exosomal AREG activation
of recipient cell EGFR. A similar effect was found when recip-
ient LM2-4175 cells were treated for 1 hr prior to AREG exo-
some incubation with an EGFR-neutralizing monoclonal anti-
body (mAb 528) (not shown), which also decreases exosomal
internalization (see below).
Exosomal AREG stability and packaging
To begin addressing why AREG exosomes impart enhanced
invasiveness compared to TGFa or HB-EGF exosomes, we
tested the stability of exosomal EGFR ligands. Baseline levels
of exosomal membrane-bound ligands were determined by
ELISA. Exosomes were incubated in the presence or absence
of the metalloprotease inhibitor galardin for 1 and 24 hr [20];
ligand concentrations were again determined, and the results
were expressed as the percent of exosomal ligand compared
to the baseline. There is little difference in the percent of exo-
somal AREG at one or 24 hr compared to TGFa or HB-EGF
(Table S1), suggesting AREG exhibits greater membrane
stability in exosomes than TGFa or HB-EGF, likely due to its
resistance to membrane cleavage despite the presence of
mature, active ADAM-10 andADAM-17 in exosomes (Figure 1A
and [6]).
We utilized quantitative confocal microscopy to determine
howmanymolecules of AREG are present in a single exosome.
Fluorescent intensity of individual exosomes purified from
MDCK cells stably expressing EGFP-tagged AREG (AREG-
EGFP exosomes) was correlated to the number of AREG-
EGFP molecules by comparison to known concentrations of
purified EGFP protein. A histogram of the AREG-EGFP mole-
cules per exosome shows an average of 24 AREG-EGFPmole-
cules (24.06 7.6) present in an individual exosome (Figure 3A).
We speculate that both the relative membrane stability and
compact packaging within exosomes contribute to the
enhanced invasive effect of AREG exosomes.
AREG Exosomes Are Rapidly Internalized
Tobegin characterizing the interaction of exosomeswith recip-
ient cells, we tested whether LM2-4175 cells internalize AREG
exosomes. LM2-4175 cells were incubated for 1–60 min with
AREG exosomes stained with DiD, a fluorescent, lipophilic,
membrane-diffuse dye. By flow cytometry, we determined
the initial recipient cell mean DiD fluorescent intensity. We
then incubated cells with Sudan Black to quench surface-
bound DiD, and we repeated flow cytometry to quantitate the
percent of cells with internalized DiD-stained exosomes. The
majority of cells internalized exosomes by 10 min, indicating
rapid uptake (Figure 3B). At this time point, recipient cell
pretreatment with the EGFR mAb 528 resulted in a 50%
decrease in the percent of internalized DiD-stained exosomes
(percent quenched of total mean intensity) (Figure 3E), sug-
gesting AREG exosome internalization is mediated, at least in
part, by recipient cell EGFR.
To substantiate exosome internalization by recipient cells,
we coincubated DiD-stained AREG exosomes or AREG-EGFP
exosomes with LM2-4175 cells for 30 min, stained the plasma
membranewith concanavalinA (ConA), and viewed internaliza-
tion by confocal microscopy. The results suggest that AREG
exosomes are internalized as indicated by the intracellular
punctate, vesicle-like structures in the xy (Figures 3C and 3D)
and xz (Figure 3D; Movie S1 and Movie S2) planes. Thus, visu-
alization of exosomal membranes and epitope-tagged AREG
demonstrates internalization of AREG exosomes.Mutant KRAS Status Correlates with Exosomal AREG
Levels and Invasive Potential
Exosomes are detected in the serum of cancer patients [5, 10];
however, it is unknownwhether differences in the composition
and behavior of exosomes exist between normal and trans-
formedcells. To test this,we examined the composition of exo-
somes fromacolorectal cancer cell line, DLD-1, containing one
wild-type and one mutant activated KRAS allele and its
isogenic derivatives in which the mutant allele (DKs-8) or
wild-typeallele (DKO-1)waseliminatedbyhomologous recom-
bination [21]. In contrast to their transformed counterparts,
DKs-8 cells do not grow in soft agar or form tumors in nude
mice. The EGFR ligand composition of DLD-1 cell exosomes
was examined by FAVS; 42% stained individually for TGFa,
58.5% stained for HB-EGF, and 84.3% stained for AREG,
whereas 28.5% of exosomes contained all three ligands (Table
S2). These results suggest that different exosome populations
in these cells contain varying amounts of EGFR ligands.
We next determined howmuch AREG was in exosomes and
WCL from DLD-1, DKO-1, and DKs-8 cells. Figure 4A shows
a higher concentration of AREG in exosomes than in WCL in
DLD-1 cells and its isogenic variants. Furthermore, there is
an enrichment of AREG in the exosomes of cells with a mutant
KRAS allele (DLD-1 and DKO-1). AREG immunoblotting of
exosomes and WCL (Figure 4B) correlated with the AREG
ELISA results (Figure 4A). The more slowly migrating bands
above the 55 KDa AREG isoform in DKO-1 and DLD-1 exo-
somes might represent a post-translational modification (Fig-
ure 4B), but future studies are needed to substantiate this
possibility.
We next addressed whether the status of donor cell lines
with regard to the KRAS mutant allele correlates with exo-
some-induced invasiveness of recipient cells. Figure 4C
shows a correlation between levels of exosomal AREG and
the ability to enhance invasion of recipient cells. Together,
these data show that AREG is enriched in exosomes from
mutant KRAS cells and that these exosomes increase recip-
ient cancer cell invasion, supporting previous reports impli-
cating a possible role for wild-type KRAS as a tumor
suppressor [22, 23].
In summary, we show that multiple cell lines produce exo-
somes containing EGFR ligands displayed in a signaling-
competent orientation. AREG exosomes enhance invasion of
recipient cells in comparison to TGFa and HB-EGF exosomes
and equivalent amounts of recombinant AREG. A single exo-
some contains an average of 24 membrane-stable AREG
molecules, and AREG exosomes are rapidly internalized by
recipient cells, which is at least partly dependent on AREG-
EGFR binding. We postulate that exosomes are multivalent
EGFR ligand signaling platforms, whereby exosomal pack-
aging acts to concentrate AREG in amanner allowing aggrega-
tion and oligomerization of recipient cell EGFR during ligand
engagement. We propose ExTRAcrine (exosomal targeted
receptor activation) as a new mode of EGFR ligand signaling
that might act in local or distant environments (see below).
In addition, we show that isogenically matched nontrans-
formed and transformed cells differ in the composition and
behavior of their exosomes; mutant KRAS status correlates
with increased exosomal AREG levels and invasiveness of
recipient cells.
These results raise intriguing possibilities about the role(s) of
exosomes in cancer. Cancer cell exosomes might act locally
and contribute to the well-recognized, but poorly understood,
cancer field effect [24, 25]. In addition, exosomes secreted by
Figure 3. Compact Packaging and Rapid Internalization of AREG Exosomes
(A) Exosomes were isolated from conditioned medium of MDCK cells stably expressing EGFP-tagged AREG. The number of GFP molecules per exosome
was determined as described in the Experimental Procedures. Each exosome contains approximately 24 AREG molecules.
(B) DiD-stained exosomes were purified from wild-type AREG-expressing MDCK cells and incubated with LM2-4175 cells for the indicated times. Flow-
cytometric analysis was performed as described in the Experimental Procedures. Data represent the mean 6 SD, p < 0.005 (**).
(C) Exosomes from nontagged AREG-expressing MDCK cells were incubated with the fluorescent membrane stain DiD (red). LM2-4175 recipient cells were
incubated with DiD-labeled AREG exosomes for the indicated times, the cell surface was labeled with ConA (green), and uptake was visualized by confocal
microscopy. Scale bars represent 5 mm.
(D) Exosomes fromC-terminally EGFP-tagged, AREG-expressingMDCK cells were purified and incubatedwith LM2-4175 cells for 30min, and internalization
wasmonitored byGFP fluorescence under confocal microscopy; the surfaces of recipient cells were labeledwith ConA (red). Two xz planes are shown: apical
surface (upper) and mid-cell (lower). Scale bars represent 5 mm.
(E)LM2-4175cellswerepretreated in thepresence (EGFRmAb)or absence (CTL)of 20mg/mlEGFRmAb528 for1hr and then incubatedwithDiD-stainedAREG
exosomes for 10 min. Flow-cytometric analysis was performed as described in the Experimental Procedures. Data represent the mean6 SD, p < 0.0001 (*).
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783tumor cells might enter the bloodstream and deposit in distant
sites, providing a hospitable environment (‘‘priming the meta-
static niche’’) in which circulating EGFR-overexpressing tumor
cells can lodge [26, 27]. Future studies will test these and other
possibilities, including additional biological effects of exo-
somes and the attendant signaling cascades they initiate.Experimental Procedures
Reagents and Antibodies
All cell culture reagents were from HyClone (Logan, UT) unless otherwise
stated. Fluorescent probes, including propidium iodide (PI), 1,10-dioctadecyl-
3,3,30,30-tetramethyl-indodi-carbocyanineperchlorate (DiD), andall secondary
antibodies used in FAVS were purchased from Invitrogen-Molecular Probes
Figure 4. Mutant KRAS Colon Cancer Cells Have Higher Exosomal AREG Protein Levels, and Mutant KRAS Exosomes Increase Invasiveness
of Recipient Cells
(A) Whole-cell lysates (WCL) or exosomes were isolated from the indicated cell lines, and the concentration of AREG was determined by ELISA. Data repre-
sent the mean 6 SD.
(B) AREG immunoblots of exosomes or WCL.
(C) LM2-4175 cells were incubated for 2 hr with serum-free medium containing 20 ng/ml exogenous (recombinant human) AREG or 100 mg of the indicated
exosomes, and the previously described invasion assay was performed. Data represent the mean 6 SD, p < 0.001 (*).
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784(Carlsbad,CA).TheAREGectodomainantibody6R1C2.4 [28, 29]wasobtained
from Bristol Myers Squib (Seattle, WA). The TGFa cytoplasmic tail antibody
wasmade incollaborationwithCovance (Princeton,NJ),and theTGFaectodo-
main antibody was made in collaboration with East Acres Biologicals (South-
bridge, MA) [30, 31]. The mouse HB-EGF antibody (MAB259) was purchased
from R&D Systems (Minneapolis, MN). Dr. Hideo Masui (Memorial Sloan-
Kettering Cancer Center) generously provided the EGFR mouse monoclonalantibody 528. The human AREG-, TGFa- and HB-EGF-specific sandwich
ELISA kits were purchased from R&D Systems. Polyclonal antibodies to
ADAM-10 and ADAM-17were purchased fromMillipore (Billerica, MA).Mouse
monoclonal antibodies to Hsp70, lamin A/C, and CD9, rabbit polyclonal anti-
body to PARP, and goat polyclonal antibody to calreticulin were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA). The rabbit polyclonal anti-
body to VDAC was purchased from Abcam (Cambridge, MA). The mouse
AREG Exosomes Increase Cancer Cell Invasion
785monoclonal antibodies to Tsg101 and flotillin-1were obtained fromBDBiosci-
ences (SanJose,CA).All other chemicals andantibodieswerepurchased from
Sigma (St. Louis, MO).
Isolation of Exosomes
Native and elicited exosome pellets were pooled and subjected to sucrose-
gradient fractionation or differential centrifugation as described in the
Supplemental Experimental Procedures.
Electron Microscopy
See Supplemental Experimental Procedures.
Biochemical Analysis
For immunoblotting, SDS-PAGE under reducing conditions was used for all
blots except for AREG blots, which were separated under nonreducing
conditions. Standard conditions were used for electrotransfer of samples
to nitrocellulose or PVDF Immobilon membranes, and blots were blocked
with non-fat milk or BSA in TBS-T according to the manufacturer’s instruc-
tions. Blots were probed with the indicated antibodies.
Fluorescence-Activated Vesicle Sorting (FAVS)
FAVS analysis was performed as previously described [8, 32]. For a more
detailed description, see Supplemental Experimental Procedures.
Invasion Assay
LM2-4175 cells were cultured in complete DMEM supplemented with 10%
bovine growth serum to 70% confluence, washed three times with PBS,
and thenmaintained overnight in serum-free DMEM. Invasion was assessed
by a modified Boyden chamber assay and a modified wound-healing assay
(detailed in Supplemental Experimental Procedures).
Quantitative Assay of EGFP Molecules
For quantification of the number of AREG-EGFP molecules per exosome,
4 ml of a purified exosome suspension was sandwiched between a glass
slide and a poly-L-lysine-coated 22 mm square coverslip. The poly-L-lysine
coating was used for exosome immobilization. For further details on image
capture and processing, see Supplemental Experimental Procedures.
Statistics
See Supplemental Experimental Procedures.
Supplemental Information
Supplemental Information includes Supplemental Experimental Proce-
dures, three figures, two tables, and two movies and can be found with
this article online at doi:10.1016/j.cub.2011.03.043.
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